Citations

Showing 10 of 108119 citations.

Re: Lack of online video educational resources for open colorectal surgery training
Shaikh, Nizamuddin , Azevedo, Rafael Ulysses de, Rajesh, Aashish , Farley, David R. , de Azevedo, Rafael U

Mayo Clinic

ANZ Journal of Surgery | April 30, 2019 | Volume: 89 | Issue: 5 | Pages: 618-618

10.1111/ans.15243 | PMID 31034152 Get It

Reply to Barbosa and Müller
Olson, Thomas P. , Smith, Joshua R , Smith, Joshua R.

Mayo Clinic

Experimental Physiology | April 30, 2019 | Volume: 104 | Issue: 5 | Pages: 777-778

10.1113/ep087618 | PMID 31034116 Get It

A phase 1 and randomized controlled phase 2 trial of the safety and efficacy of the combination of gemcitabine and docetaxel with ontuxizumab (MORAb‐004) in metastatic soft‐tissue sarcomas
Jones, Robin L. , Chawla, Sant P. , Attia, Steven , Schöffski, Patrick , Gelderblom, Hans , Cesne, Axel Le, Patel, Shreyaskumar , Wagner, Andrew J. , Heyburn, John, Weil, Susan C., Viele, Kert , Maki, Robert G. , Maki, Robert G , Jones, Robin L , Gelderblom, Hans , Chmielowski, Bartosz , Tine, Brian A. Van , Trent, Jonathan C. , Chugh, Rashmi , Wang, Wenquan

Mayo Clinic

Cancer | April 30, 2019 | Volume: 125 | Issue: 14 | Pages: 2445-2454

10.1002/cncr.32084 | PMID 31034598 Get It

Background Ontuxizumab, a humanized monoclonal antibody, targets endosialin (tumor endothelial marker 1 [TEM‐1] or CD248), which is expressed on sarcoma cells and is believed to be involved in tumor angiogenesis. This is the first trial to evaluate ontuxizumab in patients with sarcoma. Methods Part 1 was an open‐label, dose‐finding, safety lead‐in: 4, 6, or 8 mg/kg with gemcitabine and docetaxel (G/D; 900 mg/m 2 gemcitabine on days 1 and 8 and 75 mg/m 2 docetaxel on day 8). In part 2, patients were randomized in a double‐blind fashion in 2:1 ratio to ontuxizumab (8 mg/kg) or a placebo with G/D. Randomization was stratified by 4 histological cohorts. Results In part 2 with 209 patients, no significant difference in progression‐free survival between ontuxizumab plus G/D (4.3 months; 95% confidence interval [CI], 2.7‐6.3 months) and the placebo plus G/D (5.6 months; 95% CI, 2.6‐8.3 months) was observed ( P = .67; hazard ratio [HR], 1.07; 95% CI, 0.77‐1.49). Similarly, there was no significant difference in median overall survival between the 2 groups: 18.3 months for the ontuxizumab plus G/D group (95% CI, 16.2‐21.1 months) and 21.1 months for the placebo plus G/D group (95% CI, 14.2 months to not reached; P = .32; HR, 1.23; 95% CI, 0.82‐1.82). No significant differences between the treatment groups occurred for any efficacy parameter by sarcoma cohort. The combination of ontuxizumab plus G/D was generally well tolerated. Conclusions Ontuxizumab plus G/D showed no enhanced activity over chemotherapy alone in soft‐tissue sarcomas, whereas the safety profile of the combination was consistent with G/D alone.
Lipid Droplet Formation and Lipophagy in Fatty Liver Disease
Schulze, Ryan J. , McNiven, Mark A.

Mayo Clinic

Seminars in Liver Disease | April 30, 2019 | Volume: 39 | Issue: 03 | Pages: 283-290

10.1055/s-0039-1685524 | PMID 31041790 Get It

AbstractLipid droplets (LDs) are key sites of neutral lipid storage that can be found in all cells. Metabolic imbalances between the synthesis and degradation of LDs can result in the accumulation of significant amounts of lipid deposition, a characteristic feature of hepatocytes in patients with fatty liver disease, a leading indication for liver transplant in the United States. In this review, the authors highlight new literature related to the synthesis and autophagic catabolism of LDs, discussing key proteins and machinery involved in these processes. They also discuss recent findings that have revealed novel genetic risk factors associated with LD biology that contribute to lipid retention in the diseased liver.
Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report
Brunet, Mercè , Gelder, Teun van , Åsberg, Anders , Haufroid, Vincent , Hesselink, Dennis A. , Langman, Loralie J., Lemaı̂tre, F. , Marquet, Pierre , Seger, Christoph , Shipkova, Maria , Vinks, Alexander A. , Wallemacq, Pierre, Wieland, Eberhard , Woillard, Jean‐Baptiste , Barten, Markus J. , Budde, Klemens , Colom, Helena , Johnson‐Davis, Kamisha L. , Kunicki, Paweł K. , Mathew, Binu , Millán, Olga , Mizuno, Tomoyuki , Monchaud, Caroline , Noceti, Ofelia , Picard, Nicolas , Schaik, Ron HN van , Sommerer, Claudia , Vethe, Nils Tore , Winter, Brenda C. M. de , Christians, Uwe , Bergan, Stein , Langman, Loralie, Budde, Klemens , Dieterlen, Maja‐Theresa , Elens, Laure , MacPhee, Iain A. M. , Masuda, Satohiro , Moes, Dirk Jan A. R. , Pawiński, Tomasz

Mayo Clinic

Therapeutic Drug Monitoring | April 30, 2019 | Volume: 41 | Issue: 3 | Pages: 261-307

10.1097/ftd.0000000000000640 | PMID 31045868 Get It

Abstract: Ten years ago, a consensus report on the optimization of tacrolimus was published in this journal. In 2017, the Immunosuppressive Drugs Scientific Committee of the International Association of Therapeutic Drug Monitoring and Clinical Toxicity (IATDMCT) decided to issue an updated consensus report considering the most relevant advances in tacrolimus pharmacokinetics (PK), pharmacogenetics (PG), pharmacodynamics, and immunologic biomarkers, with the aim to provide analytical and drug-exposure recommendations to assist TDM professionals and clinicians to individualize tacrolimus TDM and treatment. The consensus is based on in-depth literature searches regarding each topic that is addressed in this document. Thirty-seven international experts in the field of TDM of tacrolimus as well as its PG and biomarkers contributed to the drafting of sections most relevant for their expertise. Whenever applicable, the quality of evidence and the strength of recommendations were graded according to a published grading guide. After iterated editing, the final version of the complete document was approved by all authors. For each category of solid organ and stem cell transplantation, the current state of PK monitoring is discussed and the specific targets of tacrolimus trough concentrations (predose sample C 0 ) are presented for subgroups of patients along with the grading of these recommendations. In addition, tacrolimus area under the concentration–time curve determination is proposed as the best TDM option early after transplantation, at the time of immunosuppression minimization, for special populations, and specific clinical situations. For indications other than transplantation, the potentially effective tacrolimus concentrations in systemic treatment are discussed without formal grading. The importance of consistency, calibration, proficiency testing, and the requirement for standardization and need for traceability and reference materials is highlighted. The status for alternative approaches for tacrolimus TDM is presented including dried blood spots, volumetric absorptive microsampling, and the development of intracellular measurements of tacrolimus. The association between CYP3A5 genotype and tacrolimus dose requirement is consistent (Grading A I). So far, pharmacodynamic and immunologic biomarkers have not entered routine monitoring, but determination of residual nuclear factor of activated T cells–regulated gene expression supports the identification of renal transplant recipients at risk of rejection, infections, and malignancy (B II). In addition, monitoring intracellular T-cell IFN-g production can help to identify kidney and liver transplant recipients at high risk of acute rejection (B II) and select good candidates for immunosuppression minimization (B II). Although cell-free DNA seems a promising biomarker of acute donor injury and to assess the minimally effective C 0 of tacrolimus, multicenter prospective interventional studies are required to better evaluate its clinical utility in solid organ transplantation. Population PK models including CYP3A5 and CYP3A4 genotypes will be considered to guide initial tacrolimus dosing. Future studies should investigate the clinical benefit of time-to-event models to better evaluate biomarkers as predictive of personal response, the risk of rejection, and graft outcome. The Expert Committee concludes that considerable advances in the different fields of tacrolimus monitoring have been achieved during this last decade. Continued efforts should focus on the opportunities to implement in clinical routine the combination of new standardized PK approaches with PG, and valid biomarkers to further personalize tacrolimus therapy and to improve long-term outcomes for treated patients.
Therapy With 177Lu-DOTATATE: Clinical Implementation and Impact on Care of Patients With Neuroendocrine Tumors
Hálfdánarson, Þorvarður R. , Packard, Annie T. , Dundar, Ayca , Subramaniam, Rathan M. , Packard, Annie, Halfdanarson, Thorvardur R , Kendi, A. Tuba

Mayo Clinic

American Journal of Roentgenology | April 30, 2019 | Volume: 213 | Issue: 2 | Pages: 309-317

10.2214/ajr.19.21123 | PMID 31039017 Get It

Utility and Outcomes of Imaging Evaluation for Palpable Lumps in the Postmastectomy Patient
Hayward, Jessica H. , Woodard, Genevieve A. , Joe, Bonnie N. , Lee, Amie Y. , Dashevsky, Brittany Z.

Mayo Clinic

American Journal of Roentgenology | April 30, 2019 | Volume: 213 | Issue: 2 | Pages: 464-472

10.2214/ajr.18.20550 | PMID 31039027 Get It

The Effect of Recording Montage and Tone Burst Duration on Cervical and Ocular Vestibular Evoked Myogenic Potential Latency and Amplitude
Smith, Kaylee , McCaslin, Devin L. , Jacobson, Gary P. , Burkard, Robert, Smith, Kaylee J.

Mayo Clinic

American Journal of Audiology | April 30, 2019 | Volume: 28 | Issue: 2 | Pages: 300-307

10.1044/2018_aja-17-0055 | PMID 31038981 Get It

Objectives The objectives of this study were (a) to investigate the optimal tone burst duration when recording the cervical vestibular evoked myogenic potential (cVEMP) and the ocular vestibular evoked myogenic potential (oVEMP) and (b) to determine whether monopolar recording influences the latency or amplitude of the cVEMP or the oVEMP. Method Fifteen subjects ( M = 27.7 years, SD = 6.73 years) participated in this study. The participants had no prior history of otological or neurological disease. Both oVEMPs and cVEMPs were recorded at a fixed stimulus level for stimulus durations of 2, 5, 10, and 25 ms. For both cVEMP and oVEMP, responses were obtained using a traditional differential recording montage and a monopolar recording montage. Results The cVEMP and the oVEMP had the greatest amplitude in the 2-ms stimulus condition. There was a statistically significant decrease in amplitude for durations greater than 2 ms. Monopolar and bipolar cVEMP and oVEMP latencies and amplitudes were not significantly different. Conclusion As stimulus duration increased beyond 2 ms, the amplitude of the response decreased for both the cVEMP and the oVEMP. There was no significant change in latency with increasing stimulus duration for either response. These results suggested the optimal stimulus duration for both the oVEMP and cVEMP is 2 ms, and there is no apparent advantage of using a bipolar recording technique.
Mavacamten Treatment for Obstructive Hypertrophic Cardiomyopathy
Lester, Steven J., Owens, Anjali , Wang, Andrew , Lambing, Joseph L., Semigran, Marc J., Sehnert, Amy J. , Wang, Andrew , Heitner, Stephen B. , Jacoby, Daniel Louis , Zhang, David D. , Lee, June

Mayo Clinic

Annals of Internal Medicine | April 30, 2019 | Volume: 170 | Issue: 11 | Pages: 741-748

10.7326/m18-3016 | PMID 31035291 Get It